📰 Ipca Laboratories News
Page 20 - Ipca Laboratories News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ipca Laboratories. Real-time updates on events, politics, business and more.
April 27, 2023
Motilal Oswal recommended Neutral rating on IPCA Laboratories with a target price of Rs 760 in its research report dated April 26, 2023.
April 26, 2023
Prabhudas Lilladher recommended hold rating on Ipca Laboratories with a target price of Rs 750 in its research report dated April 25, 2023.
April 26, 2023
Based on the OI percentage, 87 stocks were on the short-covering list. These included Dalmia Bharat, Bharat Electronics, Aarti Industries, Tata Consumer Products and Escorts.
April 26, 2023
Top gainers on the Nifty included Power Grid Corporation, Nestle India, Tata Consumer Products, IndusInd Bank and L&T, while losers were Hindalco Industries, Adani Ports, Bajaj Auto, Bajaj Finserv and NTPC.
April 25, 2023
BENGALURU, April 25 (Reuters) - Indian shares were little changed on Tuesday as investors await key quarterly results in a busy earnings week. The Nifty 50 was up 0.03% to 17,749.35, as of 9:51 a.m. IST, while t... | 12:23am
April 25, 2023
In today’s edition of Moneycontrol Pro Panorama: Ipcas acquisition of Unichem, branch banking makes a comeback, AI not a threat to traders, Congresss do-or-die battle in Karnataka, and more
April 25, 2023
Ipca Labs plans to acquire a 33.38 percent stake in Unichem Labs at Rs 400 per share, aggregating around Rs 1,034.06 crores.
April 25, 2023
The 30-share BSE Sensex pack fell 33 points or 0.05 per cent to trade at 60,023, while the broader NSE Nifty moved 9 points or 0.05 per cent down to trade at 17,734. Mid- and small-cap shares were mixed as Nifty Midcap 100 shed 0.16 per cent and small-cap rose 0.18 per cent.
April 25, 2023
Bajaj Finance, Adani Enterprises, Britannia Industries, Bajaj Finserv and IndusInd Bank were the major Nifty gainers, while losers included HDFC Life, UPL, HDFC Bank, HDFC and Tech Mahindra
April 25, 2023
IPCA Labs: Motilal Oswal Securities said the acquisition is expensive, given increased competition in the US generics oral solids space, rising regulatory risks, strong efforts needed to turnaround Unichem,